SO
SONM.US DNA X, Inc.
- Market cap
- USD 3.08M
- P/E
- -
- P/B
- 0.74x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SONM.US undervalued?
Graham numberThe Graham number of DNA X, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
DNA X, Inc. fundamental analysis
No fundamental analysis for DNA X, Inc. yet.
DNA X, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About DNA X, Inc.
DNA X, Inc. provides cryptocurrency trading services worldwide. The company operates a cryptocurrency trading platform that allows users to trade and swap cryptocurrencies for other cryptocurrencies or cash-equivalent currencies. It markets its services through word of mouth and earned media on social media platforms. The company serves individual cryptocurrency traders. The company was formerly known as Sonim Technologies, Inc. and changed its name to DNA X, Inc. in January…
Full company profileDNA X, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
DNA X, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.85M | 59.0M | 136M | 116M | 64.0M | 54.6M | 69.8M | 93.6M | 58.3M | 0.00 | -88.3M |
| Gross Profit | 1.13M | 20.3M | 48.1M | 34.5M | 15.2M | 6.41M | 11.6M | 19.3M | 9.92M | -4.30M | -30.9M |
| Operating Income | - | -6.77M | 5.39M | -22.4M | -29.3M | -38.0M | -14.3M | 513K | -33.6M | -5.41M | -9.79M |
| EBITDA | - | -6.25M | 5.71M | -19.4M | -27.0M | -36.3M | -11.4M | 2.51M | -29.8M | -2.17M | -9.52M |
| Net Income | - | -8.52M | 1.28M | -25.8M | -29.9M | -38.6M | -14.1M | -90.0K | -33.6M | -20.7M | 10.2M |
| EPS | - | -766 | 115 | -2,500 | -1,166 | -735 | -88 | -0.39 | -128 | -29 | 7.54 |
| Balance Sheet | |||||||||||
| Total Assets | 1.05M | 30.2M | 67.3M | 55.5M | 50.3M | 41.1M | 53.7M | 56.0M | 39.7M | 43.9M | 4.52M |
| Total Liabilities | 4.05M | 39.8M | 62.2M | 29.9M | 21.9M | 22.5M | 33.6M | 33.7M | 45.4M | 50.6M | 5.75M |
| Shareholders' Equity | -2.99M | -9.51M | 5.13M | 25.5M | 28.4M | 18.6M | 20.0M | 22.4M | -5.70M | -6.73M | -1.23M |
| Cash & Short-term Investments | 103K | 1.58M | 13.0M | 11.3M | 22.1M | 11.2M | 13.2M | 9.40M | 5.34M | 1.30M | 900K |
| Total Debt | - | 10.7M | 13.5M | 10.2M | 362K | 214K | 213K | 55.0K | - | 5.07M | 2.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -8.91M | 3.86M | -33.5M | -10.6M | -38.5M | -12.4M | -4.05M | -8.49M | -23.5M | -10.9M |
| Capital Expenditure | 69.0K | 1.17M | 2.55M | 1.36M | 11.0K | 46.0K | 8.00K | 36.0K | 214K | 0.00 | 188K |
| Free Cash Flow | - | -10.1M | 1.32M | -34.9M | -10.6M | -38.5M | -12.4M | -4.09M | -8.70M | -23.5M | -11.1M |
| Ratios | |||||||||||
| ROE | - | - | 24.9% | -101.2% | -105.4% | -207.3% | -70.3% | -0.4% | - | - | - |
| ROA | - | -28.2% | 1.9% | -46.6% | -59.5% | -94.0% | -26.2% | -0.2% | -84.7% | -47.1% | 225.5% |
| Net Profit Margin | - | -14.4% | 0.9% | -22.2% | -46.8% | -70.8% | -20.2% | -0.1% | -57.7% | - | - |
| Debt to Equity | - | - | 2.63x | 0.40x | 0.01x | 0.01x | 0.01x | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
DNA X, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 6.00K | 0.23 | - |
| 2019 | USD 1.90M | 184 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:18 on Oct 27, 2025.
Who owns DNA X, Inc.
- Insiders 34.77%
- Institutions 6.05%
- Public & others 59.18%
- Shares outstanding 1.49M
- Free float 1.01M
Top funds holding SONM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 5.36K | 0.36% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.74K | 0.18% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 1.06K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 184.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding SONM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| C2C Wealth Management, LLC | 47.5K | 3.19% | +33.80% | Sep 2026 |
| BlackRock Inc | 14.0K | 0.94% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 12.7K | 0.86% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 12.6K | 0.85% | -14.98% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.90K | 0.40% | +20.63% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 4.50K | 0.30% | 0.00% | Jun 2026 |
| UBS Group AG | 2.30K | 0.15% | -93.64% | Jun 2026 |
| Tower Research Capital LLC | 642.00 | 0.04% | -2.87% | Jun 2026 |
| SBI Securities Co Ltd | 214.00 | 0.01% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 0.00 | 0.00% | -100.00% | Jun 2026 |
DNA X, Inc. company profile
- Company name
- DNA X, Inc.
- Ticker
- SONM.US
- Exchange
- USA Stocks
- Listed since
- Aug 10, 1995
- Sector
- Financial Services
- Industry
- Technology Hardware, Storage & Peripherals
- Employees
- 4
- Fiscal year end
- December
- Address
- 4445 Eastgate Mall, San Diego, CA, United States, 92121
- Phone
- 650 378 8100
- Website
- ir.dna-x.global
About DNA X, Inc.
DNA X, Inc. provides cryptocurrency trading services worldwide. The company operates a cryptocurrency trading platform that allows users to trade and swap cryptocurrencies for other cryptocurrencies or cash-equivalent currencies. It markets its services through word of mouth and earned media on social media platforms. The company serves individual cryptocurrency traders. The company was formerly known as Sonim Technologies, Inc. and changed its name to DNA X, Inc. in January 2026. DNA X, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DNA X, Inc. management
8- Mr. Michael C. MulicaExecutive Chairman & Acting CEO · born 1963
- Mr. Clayton CroliusChief Financial Officer · born 1963
- Zhide WangSenior Vice President of Global Operations
- Ms. Dyan KaplanSenior Vice President of Sales & Customer Experience
- Ms. Anette GavenVice President of Marketing
- Mr. Simon RayneSenior VP and GM of the UK, EMEA & APAC
- Zhiheng YaoHead of Global Engineering
- Stephanie SogawaVice President of Program Management